Molecular classification of breast cancer: Implications for selection of adjuvant chemotherapy

Nature Clinical Practice Oncology

Volumn 3, Issue 11, 2006, Pages 621-632

  Andre, Fabrice ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; THERAPY EFFECT;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DECISION MAKING; FEMALE; HUMANS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750541932     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0636     Document Type: Review

References (59)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: 1687-1717
2. Campone M et al. (2005) Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 16: 1343-1351
3. Doyle JJ et al. (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23: 8597-8605
4. Trudeau M et al. (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6: 886-898
5. Nowak AK et al. (2004) Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5: 372-380
6. Bast RC Jr et al. (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878
7. D'Eredita G et al. (2001) Prognostic factors in breast cancer: The predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37: 591-596
8. Olivotto IA et al. (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725
9. Rouzier R et al. (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23: 8331-8339
10. Berry DA et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658-1667
11. Guarneri V et al. (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24: 1037-1044
12. Bear HD et al. (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174
13. Pusztai L et al. (2003) Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 9: 2406-2415
14. Gruvberger S et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984
15. Rhodes A et al. (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53: 125-130
16. Bonneterre J et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18: 3748-3757
17. Mouridsen H et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
18. Lacroix M et al. (2001) Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: A comparison. Breast Cancer Res Treat 67: 263-271
19. Paik S et al. (2004) A multi gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826
20. Habel LA et al. (2005) Gene expression and breast cancer mortality in Northern California Kaiser Permanente patients: A large population-based case control study [abstract]. Proc Am Soc Clin Oncol 24: 603a
21. Paik S et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734
22. Ma XJ et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616
23. Jansen MP et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23: 732-740
24. Symmans WF et al. (2005) Measurements of estrogen receptor and reporter genes from micro arrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy [abstract]. Breast Cancer Res Treat 94 (Suppl 1): S308a
25. Loi S et al. (2005) Prediction of early relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring [abstract #509]. Proc Am Soc Clin Oncol
26. Radmacher MD et al. (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505-511
27. Perou CM et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
28. Sorlie T et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
29. Sorlie T et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423
30. Hu Z et al. (2006) The molecular portraits of breast tumors are conserved across microarray platfroms. BMC Genomics 7: 96
31. Sotiriou C et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398
32. Pusztai L et al. (2003) Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 9: 2406-2415
33. Rouzier R et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685
34. McShane LM et al. (2002) Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 18: 1462-1469
35. Milligan GW and Cooper MC (1985) An examination of procedures for determining the number of clusters in a data set. Psychometrika 50: 159-179
36. Tibshirani R et al. (2001) Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc B 63: 411-423
37. Nielsen TO et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374
38. Abd El-Rehim DM et al. (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340-350
39. Van de Rijn M et al. (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996
40. Radmacher MD et al. (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505-511
41. van't Veer LJ et al. (2001) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
42. van de Vijver MJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
43. Buyse M et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192
44. Wang Y et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679
45. Foekens JA et al. (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24: 1665-1671
46. Chang JC et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369
47. Iwao-Koizumi K et al. (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431
48. Hess KR et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 24: 4236-4244
49. Ayers M et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293
50. Gianni L et al. (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277
51. Yoshimoto M et al. (2004) Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer. 40th Annual ASCO Meeting Proceeding [abstract #500]. J Clin Oncol 22 (Suppl): A14S
52. Folgueira MA et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443
53. Modlich O et al. (2005) Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: Translation of microarray data into clinically useful predictive signatures. J Translational Med 3: 32
54. Petit T et al. (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211
55. Di Leo A et al. (2002) HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8: 1107-1116
56. Press MF et al. (2005) Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Breast Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting [abstract #1045]. Breast Cancer Res Treat 94 (Suppl 1): S32
57. Fedier A et al. (2003) p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. Int J Oncol 23: 1431-1437
58. Geisler S et al. (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512
59. Bertheau P et al. (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360: 852-854